Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway

Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway

Castration-resistant prostate cancer (CRPC) is a progressed stage of prostate cancer, which requires better understanding of the mechanisms and remains an unmet clinical need. As a common oncogene, K-Ras is associated with malignant behavior in different types of tumors but its role in CRPC is unkno...

Full description

Bibliographic Details
Main Authors: Jiayu Liu, Yongbo Zheng, Yingying Gao, Zhen Quan, Bo Qiao, Luo Li, Ting Li, Limei Duan, Jinxiao Yang, Chunli Luo, Xiaohou Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
KRAS mutation G12C
inhibitor 9
castration-resistant prostate cancer
drug resistance
metastasis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00075/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00075/full

Similar Items